Incidental Aggravation of Venous Malformation After Botulinum Toxin Type A Injection for Reducing Benign Masseteric Hypertrophy

Abstract

Botulinum toxin type A was first produced as a commercially available product in 1989. After many years and considerable experience with this product, botulinum toxin type A is currently used worldwide, and the observations and effects supported by good experimental data provide a rationale regarding treatment protocols for use of botulinum toxin type A in a variety of disorders. Especially in cosmetic medicine, such as the treatment of facial rhytides and benign masseteric hypertrophy, botulinum toxin type A is in widespread use, and the results are regarded as good.1 We managed a case involving the incidental aggravation of a venous malformation after injecting a woman with benign masseteric hypertrophy with botulinum toxin type A and without recognizing the venous malformation in the mandibular angle.